Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373624 | 0.92 | TGFBR1 (0.68) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL415954 | 0.89 | TGFBR1 (0.63) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL373361 | 0.84 | TGFBR1 (0.67) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL373272 | 0.83 | TGFBR1 (0.65) | TGFBR1MAPK14RIPK2ACVR1BADORA2B | |
| SCHEMBL373508 | 0.81 | TGFBR1 (0.65) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL414478 | 0.81 | TGFBR1 (0.69) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL373384 | 0.79 | TGFBR1 (1.00) | TGFBR1MAPK14 | |
| SCHEMBL373250 | 0.79 | TGFBR1 (0.42) | TGFBR1 | |
| SCHEMBL250242 | 0.78 | TGFBR1 (0.55) | TGFBR1MAPK14 | |
| SCHEMBL373625 | 0.77 | TGFBR1 (1.00) | TGFBR1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871744-B2 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partyers, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B&G PARTNERS, LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2409708-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partners, LLC (US) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | MUC1, NEU4, ALK | TGFBR1 1324/4885MAPK14 2025/4885MAPK13 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.